GNBT,
Generex Awarded New Pain Relief Patents
Wednesday November 19, 10:16 am ET
Company Expands Patent Portfolio in Mexico and New Zealand
WORCESTER, Mass., Nov. 19, 2008 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News) (http://www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has received two new patents, one in Mexico (issued by the Mexican Institute of Industrial Property), the other in New Zealand (issued by the Intellectual Property Office of New Zealand).
ADVERTISEMENT
The patents share the title, ``Pharmaceutical Compositions for Buccal Delivery of Pain Relief Medications,'' and contain claims to a pharmaceutical composition for pain relief containing a narcotic analgesic in micellar form.
``We are pleased that our patent portfolio is expanding to include the pain relief application,'' said Rose Perri, the Company's Chief Operating Officer. ``As we continue the pivotal Phase III studies of our flagship product, Generex Oral-lyn(tm), we seek additional applications for our proprietary drug platform technology.''
Generex currently holds an aggregate of 130 patents worldwide (21 of which are United States patents) and has an aggregate of 132 patent applications pending in various jurisdictions.
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in India and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. For more information, visit the Generex website at generex.com.
The Generex Biotechnology Corp. logo is available at globenewswire.com |
